Dapagliflozin

Dapagliflozin is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor used for type 2 diabetes, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease. It lowers blood glucose by reducing renal reabsorption of glucose. Mediocon Inc supplies pharmaceutical-grade Dapagliflozin meeting IP, BP, EP, and USP standards.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Type 2 diabetes mellitus (T2DM)
• Heart failure with reduced ejection fraction
• Chronic kidney disease (CKD)
• Cardiovascular risk reduction therapy

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings